← Leaderboards
Om Prakash Srivastava
University Of Alabama At Birmingham
$7,222,144
Attributed
$7,222,144
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $438.9K · FY2005–23$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,222,144 · 3
By mechanism
R01$7,120,333 · 2
P30$101,811 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Stephen Barnes$26,295,575
- Sadis Matalon$21,362,558
Others in their field
Top investigators on “Cataract”
- Raymond Kraker · Jaeb Center For Health Research, Inc.$37,848,925
- Rohit Varma · University Of Southern California$30,430,361
- Ales Cvekl · Yeshiva University$23,016,289
- Curtis L Meinert · Johns Hopkins University$22,890,517
- Wah Chiu · Baylor College Of Medicine$21,626,086
- J. Mark Cline · Wake Forest University$20,130,326
Research focus
CataractCrystallinsAgingCrosslinkProteolysisIn VivoAge RelatedLensProteinsMolecularLens OpacitiesWaterProtease InhibitorIn VitroMembraneBasePlayMouse ModelDeamidationPost-Translational Protein ProcessingTransgenic MiceInhibitor/AntagonistEnzymesN-Terminal
Grant awards (30)
Molecular Mechanism of αAN101D-Transgene-Induced Age-Related Cataract$394,771
R01 · FY2023 · EY · contact PI
Molecular Mechanism of αAN101D-Transgene-Induced Age-Related Cataract$382,927
R01 · FY2022 · EY · contact PI
Molecular Mechanism of αAN101D-Transgene-Induced Age-Related Cataract$382,927
R01 · FY2021 · EY · contact PI
Molecular Mechanism of αAN101D-Transgene-Induced Age-Related Cataract$394,587
R01 · FY2020 · EY · contact PI
Proteinase Inhibitors and Crystallin Fragments in Cataract$371,250
R01 · FY2018 · EY · contact PI
Proteinase Inhibitors and Crystallin Fragments in Cataract$96,525
R01 · FY2017 · EY · contact PI
Proteinase Inhibitors and Crystallin Fragments in Cataract$392,710
R01 · FY2016 · EY · contact PI
Proteinase Inhibitors and Crystallin Fragments in Cataract$46,204
R01 · FY2016 · EY · contact PI
Proteinase Inhibitors and Crystallin Fragments in Cataract$358,925
R01 · FY2015 · EY · contact PI
Proteinase Inhibitors and Crystallin Fragments in Cataract$358,925
R01 · FY2014 · EY · contact PI
Proteinase Inhibitors and Crystallin Fragments in Cataract$347,938
R01 · FY2013 · EY · contact PI
Proteinase Inhibitors and Crystallin Fragments in Cataract$366,250
R01 · FY2012 · EY · contact PI
Project title Proteinase Inhibitors & Crystallin Fragments in Cataract$366,250
R01 · FY2010 · EY · contact PI
Project title Proteinase Inhibitors & Crystallin Fragments in Cataract$365,833
R01 · FY2009 · EY · contact PI
Proteinase Inhbitors & Crystallin Fragments in Cataract$363,998
R01 · FY2008 · EY · contact PI
Proteinase Inhbitors & Crystallin Fragments in Cataract$317,893
R01 · FY2007 · EY · contact PI
Proteinase Inhbitors & Crystallin Fragments in Cataract$53,534
R01 · FY2007 · EY · contact PI
Proteinase Inhbitors & Crystallin Fragments in Cataract$319,682
R01 · FY2006 · EY · contact PI
Proteinase Inhbitors & Crystallin Fragments in Cataract$67,557
R01 · FY2006 · EY · contact PI
Proteinase Inhbitors &Crystallin Fragments in Cataract$322,124
R01 · FY2005 · EY
Proteinase Inhbitors &Crystallin Fragments in Cataract$25,000
R01 · FY2005 · EY
PROTEINASE INHIBITORS &CRYSTALLIN FRAGMENTS IN CATARACT$42,877
R01 · FY2004 · EY
PROTEINASE INHIBITORS &CRYSTALLIN FRAGMENTS IN CATARACT$14,516
R01 · FY2004 · EY
PROTEINASE INHIBITORS &CRYSTALLIN FRAGMENTS IN CATARACT$255,850
R01 · FY2003 · EY
PROTEINASE INHIBITORS &CRYSTALLIN FRAGMENTS IN CATARACT$255,780
R01 · FY2002 · EY
CORE--COMPUTER$0
P30 · FY2002 · EY
PROTEINASE INHIBITORS &CRYSTALLIN FRAGMENTS IN CATARACT$215,250
R01 · FY2001 · EY
CORE--COMPUTER$0
P30 · FY2001 · EY
PROTEINASE INHIBITORS &CRYSTALLIN FRAGMENTS IN CATARACT$240,250
R01 · FY2000 · EY
CORE--COMPUTER$101,811
P30 · FY2000 · EY